Le Lézard
Classified in: Health, Business
Subjects: ERN, CCA, FVT

Symbility Solutions to Announce Q2 2018 Financial Results and Host Conference Call Friday August 24, 2018


TORONTO, Aug. 17, 2018 /PRNewswire/ - Symbility Solutions Inc. ("Symbility") (TSX.V: SY), a global software company focused on modernizing the insurance industry, confirmed that it will release its second quarter financial results for the three months ended June 30, 2018, before the market opens on Friday, August 24, 2018. The press release, with accompanying financial information, will be posted on Symbility's website at www.symbilitysolutions.com and on www.sedar.com.

Symbility Solutions Inc. (CNW Group/Symbility Solutions Inc.)

Symbility will follow with a webcast and conference call Friday, August 24, at 11 a.m. EDT to review highlights of its quarterly results. All interested parties are welcome to join the live webcast, which can be accessed at https://event.on24.com/wcc/r/1804244/EA67DE9BCE2A92180ADB9C25BEB468B6. Participants may also join the conference call by dialing toll free (888) 231-8191 or (647) 427-7450 for international participants. A replay of the webcast will be available on Symbility's website. 

ABOUT SYMBILITY

Symbility (TSX.V: SY) believes in creating world-class experiences that simplify business and improve lives. With a history in modernizing insurance claims solutions for the property and health industries, Symbility has established itself as a partner that puts security, efficiency and customer experience first. Symbility PROPERTYtm brings smarter thinking to property insurance. Our strategic services team, Symbility INTERSECTtm empowers a variety of businesses with smarter mobile and IoT product development strategy, design thinking and engineering excellence. With our three segments pushing industries forward, Symbility proves that change for the better is entirely possible.  symbilitysolutions.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

All trade names are the property of their respective owners.

SOURCE Symbility Solutions Inc.


These press releases may also interest you

at 07:05
Executive War College to Address, Clinical Laboratories' and Genetic Testing Firms' Perfect Storm, involving FDA's Proposed LDT Rule, Payers Requiring Z-Codes on Genetic Test Claims, and Revisions to CLIA Regulations
Three major challenges poised to confront the nation's clinical laboratories, genetic test companies, and anatomic pathology laboratories will be major topics when a top-flight roster of lab experts, innovators, and lab leaders gather in New Orleans...

at 07:05
Surmodics to Report Second Quarter of Fiscal 2024 Financial Results on May 1
Surmodics, Inc. , a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that second quarter of fiscal year 2024 financial results will be released before the market opens on Wednesday,...

at 07:04
Health Canada Approves KEYTRUDA® as a first-line treatment for adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma in combination with fluoropyrimidine- and platinum-containing chemotherapy
Merck , known as MSD outside the United States and Canada, announced that Health Canada has granted approval of  KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in combination with fluoropyrimidine- and platinum-containing-chemotherapy, for the...

at 07:00
GLOBE LIFE INC. ANNOUNCES FIRST QUARTER 2024 EARNINGS RELEASE AND CONFERENCE CALL
Globe Life Inc. will release First Quarter 2024 earnings after the market closes on Monday, April 22, 2024.  At that time, a copy of the Company's First Quarter 2024 earnings press release and any other financial and statistical information about...

at 07:00
GenFleet Therapeutics Announces FDA's Clinical Trial Approval for GFH925 (KRAS G12C Inhibitor) Monotherapy in Phase III Registrational Study Treating Metastatic Colorectal Cancer
GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, announced US Food and Drug Administration (FDA) has granted the clinical trial approval for GFH925 (KRAS G12C inhibitor) in a...

at 07:00
Drug-Free Pain Relief Comes in the Form of Red Laser Therapy
César A. Lara, MD, introduces a groundbreaking solution for pain relief in the Tampa Bay area. Red Laser Therapy leverages the power of medical-grade red laser light to effectively address various types of pain, providing patients with a noninvasive...

More news about Health...


News published on and distributed by: